ВИКОРИСТАННЯ МЕТОДІВ БІОІНФОРМАТИКИ ДЛЯ АНАЛІЗУ КЛІТИННИХ СИГНАЛЬНИХ ШЛЯХІВ
DOI:
https://doi.org/10.32471/oncology.2663-7928.t-22-3-2020-g.9204Ключові слова:
FunCoup, біоінформатичний аналіз, клітинні сигнальні шляхи, фактори транскрипції, хронічний лімфолейкозАнотація
Мета: провести пошук клітинних сигнальних шляхів, які змінено у трансформованих В-лімфоцитах при хронічному лімфолейкозі (ХЛЛ). Об’єкт і методи: аналiз функцiональних зв’язкiв (асоцiацiй) бiлкiв родини транскрипцiйних факторiв SMAD та родини STAT було проведено з використанням бази даних та алгоритму FunCoup. Результати: використовуючи алгоритм FunCoup для аналізу функціональних зв’язків протеїнів родин SMAD і STAT показано, що основну роль у цих клітинних сигнальних шляхах відіграють протеїни SMAD4 та STAT5А. У результаті аналізу стало очевидним, що ці сигнальні шляхи перетинаються зі шляхами, які регулюють структуру хроматину. Вірогідно, що саме неактивність цілих ділянок хроматину зумовлює неможливість транскрипції SMAD4- та STAT5-залежних генів у трансформованих В-клітинах при ХЛЛ.
Посилання
Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60 (5): 277–300.
Mahlich J, Okamoto S, Tsubota A. Cost of illness of japanese patients with chronic lymphocytic leukemia (CLL), and budget impact of the market introduction of ibrutinib. Pharmacoecon Open 2017; 1 (3): 195–202.
Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017; 67 (1): 7–30.
НКРУ (http://www.ncru.inf.ua.2018).
Fabbri G, Dalla-Favera R. The molecular pathogenesis of chronic lymphocytic leukaemia. Nature reviews Cancer 2016; 16 (3): 145–162.
Scarfo L, Dagklis A, Scielzo C, et al. CLL-like monoclonal B-cell lymphocytosis: are we all bound to have it? Semin Cancer Biol 2010; 20 (6): 384–390.
Gaidano G, Foa R, Dalla-Favera R. Molecular pathogenesis of chronic lymphocytic leukemia. J Clin Invest 2012; 122 (10): 3432–8.
Gluzman DF, Sklyarenko LM, Koval SV, et al. Chronic lymphocytic leukemia and acute myeloid leukemias in structure of hematological malignancies in ukrainian population in post-chernobyl period. Oncology 2017; 19 (1): 33–44 (in Russian).
Filchenkov АА, Gluzman DF, Ivanivska ТS. New differentiative antigens of normal and neoplastic blood-forming and lymphoid cells (according to the materials of international working 10). Oncology 2019; 21 (2): 101–12 (in Russian).
Hallek M. Therapy of chronic lymphocytic leukaemia. Best Pract Res Clin Haematol 2010; 23 (1): 85–96.
Haselager MV, Kater AP, Eldering E. Proliferative Signals in Chronic Lymphocytic Leukemia; What Are We Missing? Front Oncol 2020; 10: 592205. doi: 10.3389/fonc.2020.592205.
Sivina M, Xiao L, Kim E, et al. CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia. Leukemia 2020. doi: 10.1038/s41375-020-01063-7.
Seifert M, Sellmann L, Bloehdorn J, et al. Cellular origin and pathophysiology of chronic lymphocytic leukemia. J Exp Med 2012; 209 (12): 2183–98.
Dasgupta A, Mahapatra M, Saxena R. A study for proposal of use of regulatory T cells as a prognostic marker and establishing an optimal threshold level for their expression in chronic lymphocytic leukemia. Leuk Lymphoma 2015; 56 (6): 1831–8.
Matveeva A, Kovalevska L, Kholodnyuk I, et al. The TGF-beta — SMAD pathway is inactivated in cronic lymphocytic leukemia cells. Exp Oncol 2017; 39 (4): 286–90.
Matveeva AS, Kovalevska LM Kashuba EV. SMAD4 transcription factor is localized in the cytoplasm of cells of patients with chronic lymphocytic leukemia (CLL). Factors in experimental evolution of organisms 2018; 22: 144–8.
Matveeva A, Kovalevska L, Polischuk A, Kashuba E. The IL-2-STAT5 pathway is blocked in chronic lymphocytic leukemia cells Онкология 2017; 19 (4): 247–53.
Matvieieva AS, Kovalevska LM, Ivanivska TS, et al. The STAT5 transcription factor in B-cells of patients with chronic lymphocytic leukemia. Biopolym Cell 2019; 35 (1): 30–8.
Ogata H, Goto S, Sato K, et al. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res 1999; 27 (1): 29–34.
Alexeyenko A, Sonnhammer EL. Global networks of functional coupling in eukaryotes from comprehensive data integration. Genome Res 2009; 19 (6): 1107–16.
Schmitt T, Ogris C, Sonnhammer EL. FunCoup 3.0: database of genome-wide functional coupling networks. Nucleic Acids Res. 2014; 42 (Database issue): D380–388. doi: 10.1093/nar/gkt984.
Thambyrajah R, Fadlullah M, Proffitt M, et al. HDAC1 and HDAC2 Modulate TGF-beta Signaling during Endothelial-to-Hematopoietic Transition. Stem Cell Reports 2018; 10 (4): 1369–83.
Stojanovic N, Hassan Z, Wirth M, et al. HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer. Oncogene 2017; 36 (13): 1804–15.
Itoh Y, Saitoh M, Miyazawa K. Smad3-STAT3 crosstalk in pathophysiological contexts. Acta Biochim Biophys Sin (Shanghai) 2018; 50 (1): 82–90.
Shi Y, Hata A, Lo R, et al. A structural basis for mutational inactivation of the tumour suppressor Smad4. Nature 1997; 388 (6637): 87–93.
Zhao M, Mishra L, Deng C. The role of TGF-beta/SMAD4 signaling in cancer. Int J Biol Sci 2018; 14 (2): 111–23.
Peterson L, Kovyrshina T. Progression inference for somatic mutations in cancer. Heliyon 2017; 3 (4): e00277. doi: 10.1016/j.heliyon.2017.e00277.
McCarthy A, Chetty R. Smad4/DPC4. J Clin Pathol 2018; 71 (8): 661–4.
Hsu J, Sage J. Novel functions for the transcription factor E2F4 in development and disease. Cell Cycle 2016; 15 (23): 3183–90.
Hambleton S, Goodbourn S, Young D, et al. STAT2 deficiency and susceptibility to viral illness in humans. Proc Natl Acad Sci USA 2013; 110 (8): 3053–308.
Shahni R, Cale CM, Anderson G, et al. Signal transducer and activator of transcription 2 deficiency is a novel disorder of mitochondrial fission. Brain 2015; 1 38(Pt 10): 2834–46.
Ho J, Pelzel C, Begitt A, et al. STAT2 is a pervasive cytokine regulator due to its inhibition of STAT1 in multiple signaling pathways. PLoS Biol 2016; 14 (10): e2000117. doi: 10.1371/journal.pbio.2000117.
Heltemes-Harris LM, Farrar MA. The role of STAT5 in lymphocyte development and transformation. Curr Opin Immunol 2012; 24 (2): 146–52.
Dumas PY, Naudin C, Martin-Lanneree S, et al. Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib via STAT5-and hypoxia-dependent upregulation of AXL. Haematologica 2019; 104 (10): 2017–027.
Malin S, McManus S, Busslinger M. STAT5 in B cell development and leukemia. Curr Opin Immunol 2010; 22 (2): 168–76.
Malin S, McManus S, Cobaleda C, et al. Role of STAT5 in controlling cell survival and immunoglobulin gene recombination during pro-B cell development. Nat Immunol 2010; 11 (2): 171–9.
Rajala HL, Mustjoki S. STAT5b in LGL leukemia-a novel therapeutic target? Oncotarget 2013; 4 (6): 808–9.
Rajala HL, Eldfors S, Kuusanmaki H, et al. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood 2013; 121 (22): 4541–50.
Tolomeo M, Meli M, Grimaudo S. STAT5 and STAT5 Inhibitors in Hematological Malignancies. Anticancer Agents Med Chem 2019; 19 (17): 2036–4206.
de Araujo ED, Erdogan F, Neubauer HA, et al. Structural and functional consequences of the STAT5B(N642H) driver mutation. Nat Commun 2019; 10 (1): 2517.
Nowicki MO, Falinski R, Koptyra M, et al. BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood 2004; 104 (12): 3746–53.
Kollmann S, Grundschober E, Maurer B, et al. Twins with different personalities: STAT5B-but not STAT5A-has a key role in BCR/ABL-induced leukemia. Leukemia 2019; 33 (7): 1583–97.
